XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 160 filers reported holding XENON PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.16 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,776,320 | -30.1% | 52,000 | -21.2% | 0.16% | -41.8% |
Q2 2023 | $2,541,000 | +69.6% | 66,000 | +73.7% | 0.28% | +31.2% |
Q4 2022 | $1,498,340 | -57.1% | 38,000 | -60.7% | 0.22% | -54.7% |
Q3 2022 | $3,494,000 | +53.1% | 96,800 | +29.1% | 0.48% | +33.4% |
Q2 2022 | $2,282,000 | -60.7% | 75,000 | -60.5% | 0.36% | -52.5% |
Q1 2022 | $5,802,000 | -51.0% | 189,797 | -49.9% | 0.75% | -36.8% |
Q4 2021 | $11,840,000 | +259.2% | 378,997 | +75.7% | 1.18% | +130.5% |
Q3 2021 | $3,296,000 | -24.2% | 215,697 | -7.7% | 0.51% | -23.2% |
Q2 2021 | $4,351,000 | -65.7% | 233,697 | -67.0% | 0.67% | -70.7% |
Q1 2021 | $12,675,000 | +47.7% | 708,117 | +26.9% | 2.28% | +101.6% |
Q4 2020 | $8,584,000 | +55.0% | 558,117 | +11.6% | 1.13% | -61.4% |
Q3 2020 | $5,538,000 | +76.0% | 500,264 | +99.4% | 2.94% | +63.7% |
Q2 2020 | $3,146,000 | +1997.3% | 250,897 | +1796.7% | 1.79% | +925.1% |
Q1 2020 | $150,000 | -92.9% | 13,228 | -91.8% | 0.18% | -91.4% |
Q4 2019 | $2,118,000 | – | 161,600 | – | 2.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 1,594,932 | $48,518,000 | 10.26% |
GREAT POINT PARTNERS LLC | 1,104,334 | $33,594,000 | 8.06% |
ACUTA CAPITAL PARTNERS, LLC | 272,500 | $8,289,000 | 4.62% |
DAFNA Capital Management LLC | 438,623 | $13,343,000 | 3.64% |
Parkman Healthcare Partners LLC | 294,559 | $8,960,000 | 3.30% |
Avoro Capital Advisors LLC | 4,900,000 | $149,058,000 | 2.94% |
Nan Fung Group Holdings Ltd | 114,380 | $3,479,000 | 2.39% |
BVF INC/IL | 1,597,966 | $48,610,000 | 2.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 232,630 | $7,077,000 | 2.18% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 4,391,038 | $133,575,000 | 2.16% |